IPD 0.83% 6.0¢ impedimed limited

Ann: Change of Director's Interest Notice - Mr Andrew Grant, page-47

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 52 Posts.
    lightbulb Created with Sketch. 5
    From Ord research

    Thesis supported by feedback from head doctors at Tier 1 CancerCenters...

    We interviewed senior breast cancer specialists at three of the leading cancer care centers in theUS:▪ University of Texas MD Anderson Cancer Center (NCCN Member)▪ Cleveland Clinic (NCCN Member)▪ Beth Israel Deaconess Medical CenterThese are larger breast cancer care programs, with new patients per year ranging from 800-1,500.All three groups have at least 1 SOZO, with lymphoedema prevention programs of varyingprotocols and sizes.

    Below we highlight some of the key takeaways across the calls:
    ▪ “NCCN update is a huge deal – will establish clinical practice moving forward...”
    ▪ “Reimbursement is the single most important factor for BIS adoption from here”▪ “We will wait for full reimbursement before we invest in additional SOZOs...”
    ▪ “Still higher levels of caution around capital budgets... if you can show it will be a profitcenter this will help”

    ▪ “Hard to see any major competition – data is pretty clear. We use perometry sometimesbut its highly specialised...”
    ▪ “I expect to see this universally reimbursed very soon”
    ▪ “We have historically used SOZO to measure response to surgery rather than prospectivesurveillance of at-risk patients”
    ▪ “Not just NCCN – look at recommendations from other groups like the American Societyof Breast Surgeons. Will push clinics towards prevention programs and SOZO...”

    The above are direct quotes from NCCN members that have significant breast cancer care programs and they quote "reimbursement is the single most important factor for BIS adoption from here". Can the people on here who peddle the reimbursement is not important anymore provide the source of their assertion?

    It is telling that reimbursement momentum has ground to a halt under this new board and management. Even more telling is that it has nothing to do with sales and independent of all the upheaval. Has data and all documentation been provided to insurance cos?

    It was coming thick and fast under the old board. I am starting to think the vote wasnt about a board spill. To spill a board on the verge of universal reimbursement I have to come realise was stupid. The fact the board spill agents have not supported price and stepped in is also telling.
 
watchlist Created with Sketch. Add IPD (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.